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Introduction. The burden of tuberculosis is high in eastern Malaysia, and rates of Mycobacterium tuberculosis drug resistance
are poorly defined. Our objectives were to determine M. tuberculosis susceptibility and document management after receipt
of susceptibility results. Methods. Prospective study of adult outpatients with smear-positive pulmonary tuberculosis (PTB) in
Sabah, Malaysia. Additionally, hospital clinicians accessed the reference laboratory for clinical purposes during the study. Results.
176 outpatients were enrolled; 173 provided sputum samples. Mycobacterial culture yielded M. tuberculosis in 159 (91.9%) and
nontuberculous Mycobacterium (NTM) in three (1.7%). Among outpatients there were no instances of multidrug resistant M.
tuberculosis (MDR-TB). Seven people (4.5%) had isoniazid resistance (INH-R); all were switched to an appropriate second-line
regimen for varying durations (4.5–9 months). Median delay to commencement of the second-line regimen was 13 weeks. Among
15 inpatients with suspected TB, 2 had multidrug resistant TB (one extensively drug resistant), 2 had INH-R, and 4 had NTM.
Conclusions. Current community rates of MDR-TB in Sabah are low. However, INH-resistance poses challenges, and NTM is
an important differential diagnosis in this setting, where smear microscopy is the usual diagnostic modality. To address INH-R
management issues in our setting, we propose an algorithm for the treatment of isoniazid-resistant PTB.
1. Introduction
Tuberculosis (TB) is a disease of major significance in east-
ern Malaysia (Malaysian Borneo), especially in Sabah state.
Eastern Malaysia has a disproportionally high burden of the
country’s TB cases [1], and Sabah’s estimated TB incidence
rate (131/100,000) [2] far exceeds national rates (80/100,000)
[3]. Rates of Mycobacterium tuberculosis drug resistance are
not well defined in Sabah. Where testing has occurred, it has
often been reserved for treatment failure cases, limiting the
generalizability of such findings.Malaysian rates ofmultidrug
resistant- (MDR-) TB have been estimated at 0.3% in 2005
and 1.3% in 2011 [4]. In unpublished data from the Sabah
state reference laboratory, 16MDR-TB cases occurred in 2011,
representing 2.1% of isolates submitted that year [5]. Isoniazid
resistance (INH-R) is reported in approximately 4% of
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Table 1: Treatment of isoniazid-resistant pulmonary tuberculosis: recommendations from selected references and level of evidence.
Treatment element Reference Study type Level of evidence∗
Drugs
R throughout [11] Meta-analysis of trials and cohortstudies III
REZ
[21] Nonrandomised trial IIa
[22] Observational study III
[17, 23] Expert opinion IV
HREZ [16] Retrospective review III
Add a fluoroquinolone in all instances (moxifloxacin 400mg or
levofloxacin 750–100mg substituted for isoniazid) [20] Expert opinion IV
Add a fluoroquinolone if pyrazinamide is not tolerated [23] Expert opinion IV
Add a fluoroquinolone if disease is extensive [18] Expert opinion IV
High-dose H is not recommended [23] Expert opinion IV
Duration
6 months (REZ) [21] Nonrandomised trial IIa
6 months (REZ) if disease is not extensive [23] Expert opinion IV
6 to 9 months (REZ) [17] Expert opinion IV
6 to 12 months (variety of regimens) [22] Observational study III
9 months (REZ) if culture-positive at 2 months [23] Expert opinion IV
Dosing frequency∗∗
Dosing should be daily during the intensive phase
[11] Meta-analysis of trials and cohortstudies III
[24] Systematic review
[23] Expert opinion IV
Dosing can be given intermittently (thrice weekly) during the
continuation phase [25] Expert opinion IV
Twice or thrice weekly RZE for 6 months in HIV negative disease [21] Nonrandomised trial IIa
∗Ia: evidence from meta-analysis of randomized controlled trials, Ib: evidence from at least one randomized controlled trial, IIa: evidence from at least one
well designed controlled trial which is not randomized, IIb: evidence from at least one well designed experimental trial, III: evidence from case, correlation,
and comparative studies, IV: evidence from a panel of experts [26].
∗∗Where dosing is self-administered rather than directly observed (as in Malaysia), there may be no advantage in an intermittent regimen.
M. tuberculosis in western Malaysia [6, 7], but rates have not
been published from eastern Malaysia.
Isoniazid resistance (INH-R) is now generally acknowl-
edged to be associated with poorer outcomes than INH-
susceptible disease [8–11]. Despite INH-R TB being so com-
mon (4–10% globally [12–14]), the level of evidence to guide
management ismostly level III-IV (Table 1), resulting in prac-
tices being nonuniform regarding drug choice, duration, and
dosing frequency.The standard short-course regimen (isoni-
azid (H), rifampicin (R), ethambutol (E), and pyrazinamide
(Z)) has traditionally been considered adequate [15, 16]. How-
ever 9months of REZ (9REZ) or variations on this theme [10,
17–19] are increasingly used, and some advocate for the addi-
tion of a fluoroquinolone routinely [20], or in extensive INH-
R pulmonary disease [18]. A new trial from the Tuberculosis
Trials Consortium [21] provides much-needed evidence in
this field; although the study was single-arm and nonran-
domised, it provides evidence that twice or thrice weekly REZ
for 6 months in HIV negative patients is mostly effective
(3.5% failed or relapsed) but poorly tolerated [21]. Poor
tolerability, especially of pyrazinamide, is a key challenge in
the treatment of INH-R pulmonary TB (PTB) and a reason
to require third-line options such as 12 months of a 2-drug
regimen [22] or substitution with a fluoroquinolone [18].
The time taken to obtain M. tuberculosis susceptibility
results is long if solid culture medium only is used, or where
results are batched for dispatch to a reference laboratory; both
these factors apply in our setting. If susceptibility results are
delayed and the patient has already been switched to HR
continuation phase treatment, the question of what to do
after a period of effectivemonotherapywith rifampicin arises.
Tailoring of regimens for pulmonary INH-R TB depending
on factors, such as patient age, HIV status, and cavitary dis-
ease, can be difficult in high TB-burden settings accustomed
to standardized regimens.
Knowledge of local susceptibility not only allows tailoring
of treatment in individuals but provides local antibiogram
data to aid clinicians in constructing regimens to use empir-
ically and in culture-negative suspected tuberculosis (e.g.,
paediatric and extrapulmonary TB) and latent TB. Our first
objective was to determine TB drug susceptibility profiles
among patients with new or retreatment pulmonary TB
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presenting to a large community TB clinic in Kota Kinabalu,
Sabah, Malaysia. Our second objective was to document
clinical practice on receipt of susceptibility results.
2. Methods
This is a prospective observational study of smear-positive
PTB outpatients, enrolled at Luyang Tuberculosis Outpatient
Clinic, Kota Kinabalu, Malaysia. This is the main referral TB
clinic in Kota Kinabalu, diagnosing and treating almost 200
patients annually. Kota Kinabalu district has a population
of approximately 600,000. Participants were enrolled over
2 years, 4 July 2012–3 July 2014. Additionally, during the
study period, clinicians at the Kota Kinabalu tertiary adult
referral hospital, Queen Elizabeth Hospital (QEH), were able
to access the services of the reference laboratory for clinical
purposes, for patients in whom mycobacterial infection,
particularly drug resistance, was suspected. QEH manages
approximately 200 smear-positive PTB inpatients annually.
2.1. Informed Consent. Potentially eligible participants were
provided with information about the study using written and
pictorial materials and explanations from research staff and
were required to provide written, informed consent. Consent
was obtained from a parent/guardian for participants aged
between 15 and 17, who additionally provided their assent.
2.2. Participants. Outpatient participants were eligible if they
had sputum smear-positive pulmonary TB, were aged ≥15
years, and had received <7 days’ TB treatment. They were
referred for enrolment by the TB clinic doctor after being
diagnosed with TB on the basis of clinical and X-ray assess-
ment, and at least one sputum positive for acid fast bacilli
(AFB) on Ziehl-Neelsen stain performed at the clinic’s smear
microscopy laboratory.
2.3. Procedures. A new sputum sample was provided on the
day of enrolment. Samples were batched in a domestic refrig-
erator and transported to an international reference lab-
oratory (Singapore General Hospital Laboratory, Singa-
pore) as described elsewhere [27]. The BACTEC Mycobac-
terium Growth Indicator Tube (MGIT) 960 tube system
was employed for culture. Drug susceptibility testing was
performed for M. tuberculosis isolates using the nonradio-
metric MGIT system for isoniazid, rifampicin, ethambutol,
streptomycin, and, in the instance of any first-line resistance,
also for ofloxacin, kanamycin, and ethionamide. Nontuber-
culous mycobacteria (NTM) were identified using a DNA
probe (ProbeTec, Becton-Dickinson). Further speciation, if
done, was achieved using a second DNA probe (INNO-LiPA
MYCOBACTERIA, Innogenetics, Ghent, Belgium) and high-
performance liquid chromatography (HPLC) of mycolic
acids.
HIV was tested using two rapid tests (Abbott Determine
HIV-1/2 and a second locally supplied point-of-care test, as
described elsewhere [28]). Positive results were confirmed
by enzyme immunoassay, particle agglutination, and line
immunoassay.
Table 2: Characteristics of outpatients enrolled at Luyang Clinic.
Baseline characteristic Number
Number 176
Age in years: median (range) 30.0 (16–73)
Male: number (%) 104 (59.0%)
Nationality
Malaysian: number (%) 117 (66.5%)
Non-Malaysian: number (%) 59 (33.5%)
HIV positive: number (%) 3 (1.7%)
Current smoker 40 (22.7%)
Past TB 13 (7.4%)
2.4. Ethical Approval. Ethical approval was obtained from
the Medical Research Ethics Committee, Malaysian Ministry
of Health, and the Health Research Ethics Committee of
Human Research Ethics Committee of the Northern Terri-
tory Department of Health and Menzies School of Health
Research, Australia.
2.5. Clinical Specimens from Hospital Patients. During the
study period, clinicians atQueen ElizabethHospital were also
able to utilise the arrangement established with the reference
laboratory. Clinicians could send sputum specimens or extra-
pulmonary samples, with the batched research specimens,
to obtain mycobacterial culture and susceptibility testing to
guide clinical management. No specific inclusion criteria
were applied apart from the suspicion of mycobacterial
infection and difficulty obtaining results locally.
2.6. Statistics. Data were analysed using Stata 13.1. (Stata
Corp., College Station, Texas, USA). Continuous variables
were compared using Student’s t-test or Wilcoxon Rank Sum
test. Categorical variables were compared using Chi-squared
or Fisher’s Exact test, as appropriate.
3. Results
3.1. Outpatients. During the 2-year study period, 176 out-
patients consented and were enrolled (Figure 1, Table 2).
Details relating to patient demographics and HIV status are
described elsewhere [28]. A sputum sample was received
by the laboratory for 173 individuals. Thirteen participants
reported having received TB treatment in the past (median
12.5 years ago according to patients’ recollection, range 1–39
years).
3.2. Outpatient Culture and Susceptibility Results. Mycobac-
terial culture was positive in 162 of 173 (93.6%) samples
received. One hundred and fifty-nine (91.9%) yielded M.
tuberculosis, and three (1.7%) yielded NTM; one was M.
fortuitum; the others were not speciated. Of patients in whom
NTM was isolated, two had underlying bronchiectasis.
Susceptibility results were unavailable in 3M. tuberculosis
isolates due to overgrowth of the culture by contaminat-
ing organisms. In the 156 isolates from outpatients with
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Table 3: Isoniazid resistance among outpatients with pulmonary tuberculosis.










Patient 1 No Yes 28 weeks RZE 6 Cured
Patient 2 No Yes 15 weeks RZE 9
Defaulted but already smear
negative and received 6
months’ treatment in total
Patient 3 No Yes 8 weeks RZE 4.5 Transferred
Patient 4 No Yes 12 weeks RZE 9 Cured
Patient 5 No Yes 11 weeks RZE 6 Cured
Patient 6 No Yes 16 weeks RZE 6 Cured
Patient 7 No Yes 8 weeks RZE 6 Cured
Median 12 Weeks
395 individuals with new TB
238 males (60.3%)










0 MDR-TB 2 not specified




∙ 128 not consenting
∙ 79 ineligible (58 referred out, 9 on TB treatment
for >5 days, 6 not referred to research nurse, 4
aged <15 yrs, 2 no smear + pulmonary TB)




Figure 1: Outpatient study diagram showing enrolment and microbiological results.
susceptibility data, none hadMDR-TB or rifampicinmonore-
sistance. Seven people (4.5%) had infection with INH-R
M. tuberculosis, none of whom recalled having previously
received TB treatment. INH-R disease was more common
in people of non-Malaysian ethnicity: 6 of the 7 (86%) were
Filipino or Indonesian, compared with 50/159 (33.6%) with
INH-S disease (𝑃 = 0.009).
One M. tuberculosis isolate with isoniazid resistance had
additional streptomycin and ethionamide resistance. One
instance of streptomycin monoresistance was also identified.
3.3. Management of Drug Resistant Cases. Among people
identified as having INH-R, there were substantial delays
between commencement of the first-line tuberculosis treat-
ment regimen and change to a second-line regimen. The
median delay was 13 weeks (range 8 to 28 weeks); see Table 3.
Opportunities for delay included the time taken to dispatch
sputum samples to the laboratory, receive the resistance
report, inform the treating doctor, and recall the patient and
for nursing staff to implement the doctor’s new treatment
regimen. The usual regimen prescribed after notification of
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15 inpatients with suspected mycobacterial infection
skin biopsy, skin swab, and toe tissue biopsy)
(1 abscess, 7 sputum)
4 NTM
(1 skin biopsy, 3 sputum)
1 histoplasmosis 
(toe biopsy)
2 no growth 




2 MDR-TB2 INH- 
resistance
∙ 11 sputum specimens




Figure 2: Hospital inpatients with suspected mycobacterial infection.
INH-R results was rifampicin, pyrazinamide, and ethambutol
(Table 3). Three patients with INH-R disease had follow-
up sputum cultures performed at two months; all three had
converted their culture to negative.
3.4. Hospital Patients. Fifteen additional samples were sub-
mitted for culture from hospital inpatients with suspected
pulmonary TB (10 patients), or suspected extrapulmonary TB
(five patients). Of those with suspected pulmonary TB, three
had prior TB treatment failure, one had defaulted, three had
unknown past treatment history, and three had underlying
lung disease.
Findings from hospital inpatients are shown in Figure 2.
Two cases of pulmonary MDR-TB, including one case of
XDR-TB, were identified, both in heavily pretreated people.
The XDR-TB case is the subject of a separate case report
[29]. Two instances of INH-R were also identified, one
monoresistant (in a pretreated patient) and one combined
with streptomycin resistance (in a TB treatment-na¨ıve health
care worker). Regarding NTM, these were isolated in speci-
mens obtained from four of the hospitalised individuals and
identified by DNA probe and HPLC as M. abscessus or M.
avium-intracellulare complex (from sputum) and M. avium-
intracellulare complex (from a skin biopsy).
4. Discussion
We have found low rates of drug resistance among outpatient
cases of tuberculosis in Sabah, Borneo, but occasional cases
ofMDR-TB in pretreated patients in the inpatient setting.The
rate of isoniazid resistance (4.5%) is, reassuringly, at the lower
end of what is reported globally [12–14]. Thus, while the TB
burden is high in eastern Malaysia, our study illustrates that
this appears to be predominantly drug-susceptible disease.
While the uncommon finding of MDR-TB reflects well on
the local TB control program, high ongoing rates of drug-
susceptible disease in relatively young people (median age
30 years) suggest that community transmission of TB is an
important area requiring targeted intervention.
TheMDR-TB rates we have found are low compared with
Malaysia’s immediate neighbours, where rates have been esti-
mated as follows in new and retreatment cases, respectively:
Singapore 0.1% new and 2.9% retreatment,Thailand 1.7% and
34.5%, Indonesia 2% and 14.7%, and Philippines 4.0% and
20.9% [30].There were few retreatment cases in our series (13
outpatients and 3 hospitalised patients) to provide an accurate
assessment among these patients, but the two cases of MDR-
TB both occurred in pretreated individuals. These low rates
also compare favourably with other member states of the
WHOWestern Pacific Region; MDR-TB rates in Papua New
Guinea, for instance, have been estimated to be at least 26%
of cases [31].
We identified substantial challenges in managing INH-
resistance, particularly in the transition from protocol-based
standardised care to tailored care. Despite Malaysian guide-
lines now recommending baseline cultures in all cases of sus-
pected TB, routine susceptibility results are generally unavail-
able; usual practice in our setting is to undertake sputum
mycobacterial cultures only for persistent smear-positivity
after two to three months of treatment. Multifactorial delays
occurred in implementing regimen changes, comprising the
delay in specimens reaching the reference laboratory, the time
taken to notify of the treating doctor, patient recall, and dis-
pensing of the new regimen. A specific challenge in this con-
text was that susceptibility results were frequently reported
after completion of intensive phase treatment, when the rou-
tine switch to HR had already been made. Arising from these
findings, we therefore developed an algorithm for managing
this situation (Figure 3), based on the evidence summarised
in Table 1. Such an algorithm does not replace clinical
judgement guided by individual patient needs but provides
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Continue HREZ until 
susceptibility result obtained
Yes No
Standard regimen (2HREZ, 
4HR)
Isoniazid resistance suspected 
(e.g., contact of INH-R TB)
Development of intolerance to rifampicin, pyrazinamide, or ethambutol
levoﬂoxacin or moxifloxacin
Isoniazid resistance confirmed
Recall patient for 
appointment
Yes
Still taking intensive phase HREZ
or was switched to continuation 
phase HR less than 4 weeks ago
No
for example, quinolone, especially if extensive disease is 
Yes No
Yes No
∙ Stop H, continue R, and restart EZ
∙ Continue REZ to complete a total of 9 months since
∙ Seek specialist advice
∙ Options include the following:
∙ Replace the missing drug with a new quinolone e.g., for example, 
∙ Use a 2-drug regimen for an extended duration e.g., for example, 12 months
∙ Stop H, continue R, and restart EZ
∙ Collect further sputum specimen for culture/DST
∙ Consult specialist about need for additional drug(s) e.g.,
H = isoniazid, R = rifampicin, E = ethambutol, Z = pyrazinamide, DST = drug susceptibility testing
∗If risk factors for drug adverse events are present (e.g., elderly, viral hepatitis) and disease is not extensive, noncavitary,
and the patient is improving, 6REZ can be used instead of 9REZ. Monthly eye reviews (acuity and colour vision)
are required when ethambutol is continued beyond 2 months
commencing first-line regimen∗
present
Figure 3: Algorithm for managing isoniazid resistance.
guidance for nonspecialists in the local health centre settings
where most outpatient TB is managed.
NTM was detected in 7 of 191 people (outpatients and
inpatients) with suspected TB. This finding illustrates the
problem of NTM colonisation or infection being mistaken
for TB, especially where smear microscopy is the diagnos-
tic mainstay. NTM infections have been noted to cause a
substantial burden of disease in our clinical practice and
elsewhere in Malaysia [32]. Rising rates have also been
reported elsewhere in Asia [33, 34]. This disease has been
relatively neglected comparedwith TB due to lower incidence
and lack of associated public health risk, yet diagnosis and
management can be far more challenging than TB and
outcomes poor. More research is required in Sabah to better
understand and optimise management of local NTM infec-
tions. Greater local access to mycobacterial culture is needed
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to aid clinicians in distinguishing NTM from TB, especially
in patients in whom NTM is more likely, that is, those with
underlying chronic lung disease.
A limitation of the study is that findings from the outpa-
tient setting cannot be extrapolated to all TB cases in Sabah
and are not representative of the inpatient setting; we have
presented results from the selected group of hospital patients
to illustrate this, but more data are required on inpatient drug
resistance rates, as well as treatment outcomes.
In conclusion, current rates of MDR-TB in the com-
munity in Sabah are low, reflecting well on local TB case
management, but INH-resistance poses challenges.Thismust
be addressed to avoid additional stepwise acquired resistance.
Improvement in local resourcing to ensure that diagnostics
such as liquid mycobacterial culture or molecular tests are
available in a timely, clinically useful fashionwould be amajor
advance in TB management in Sabah, which has Malaysia’s
highest TB burden. In the current scenario of delayed access
to susceptibility results, our proposedmanagement algorithm
can provide guidance here and in settings facing similar issues
globally.
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